Drug interactions between opioids and antiretroviral medications: Interaction between methadone, LAAM, and delavirdine

Elinore F. McCance-Katz, Petrie M. Rainey, Patrick Smith, Gene D. Morse, Gerald Friedland, Beth Boyarsky, Marc Gourevitch, Peter Jatlow

Research output: Contribution to journalArticle

Abstract

Understanding the drug interactions between antiretrovirals and opioid therapies may decrease toxicities and enhance adherence with improved HIV outcomes in opioid-dependent individuals. The authors report the results of a clinical pharmacology study designed to determine whether significant pharmacokinetic and/or pharmacodynamic interactions occur between the non-nucleoside reverse transcriptase inhibitor, delavirdine (DLV), and either methadone or leva-alpha acetyl methadol (LAAM) (n = 40). DLV significantly decreased methadone clearance (p = .018) and increased the methadone elimination half-life (p < .001) with a resultant increase in AUC of 19% and C minof 29%. The combined effect of DLV on the total concentration of LAAM and its active metabolites, norLAAM and dinorLAAM, was to significantly increase AUC by 43% (p < .001), Cmax by 30% (p = .013), and C min by 59% (p = .004) while decreasing Tmax (p = .05). Cognitive deficits over the seven-day study period as measured by the Mini-Mental State Examination, opioid withdrawal symptoms as measured by the Objective Opioid Withdrawal Scale, or complaints of adverse symptoms were not observed. Methadone and LAAM did not affect DLV concentrations. The findings from this study show that DLV treatment in methadone- or LAAM-maintained individuals results in altered opioid pharmacokinetics with an increased exposure and potential risk for opioid toxicity with methadone or LAAM treatment and an increased risk of cardiac toxicity with concomitant LAAM and DLV administration.

Original languageEnglish (US)
Pages (from-to)23-34
Number of pages12
JournalAmerican Journal on Addictions
Volume15
Issue number1
DOIs
StatePublished - 2006

Fingerprint

Delavirdine
Methadyl Acetate
Methadone
Drug Interactions
Opioid Analgesics
Area Under Curve
Pharmacokinetics
Substance Withdrawal Syndrome
Reverse Transcriptase Inhibitors
Clinical Pharmacology
Half-Life
HIV

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

McCance-Katz, E. F., Rainey, P. M., Smith, P., Morse, G. D., Friedland, G., Boyarsky, B., ... Jatlow, P. (2006). Drug interactions between opioids and antiretroviral medications: Interaction between methadone, LAAM, and delavirdine. American Journal on Addictions, 15(1), 23-34. https://doi.org/10.1080/10550490500419029

Drug interactions between opioids and antiretroviral medications : Interaction between methadone, LAAM, and delavirdine. / McCance-Katz, Elinore F.; Rainey, Petrie M.; Smith, Patrick; Morse, Gene D.; Friedland, Gerald; Boyarsky, Beth; Gourevitch, Marc; Jatlow, Peter.

In: American Journal on Addictions, Vol. 15, No. 1, 2006, p. 23-34.

Research output: Contribution to journalArticle

McCance-Katz, Elinore F. ; Rainey, Petrie M. ; Smith, Patrick ; Morse, Gene D. ; Friedland, Gerald ; Boyarsky, Beth ; Gourevitch, Marc ; Jatlow, Peter. / Drug interactions between opioids and antiretroviral medications : Interaction between methadone, LAAM, and delavirdine. In: American Journal on Addictions. 2006 ; Vol. 15, No. 1. pp. 23-34.
@article{88d18730eeac469d8c81923b72ce1198,
title = "Drug interactions between opioids and antiretroviral medications: Interaction between methadone, LAAM, and delavirdine",
abstract = "Understanding the drug interactions between antiretrovirals and opioid therapies may decrease toxicities and enhance adherence with improved HIV outcomes in opioid-dependent individuals. The authors report the results of a clinical pharmacology study designed to determine whether significant pharmacokinetic and/or pharmacodynamic interactions occur between the non-nucleoside reverse transcriptase inhibitor, delavirdine (DLV), and either methadone or leva-alpha acetyl methadol (LAAM) (n = 40). DLV significantly decreased methadone clearance (p = .018) and increased the methadone elimination half-life (p < .001) with a resultant increase in AUC of 19{\%} and C minof 29{\%}. The combined effect of DLV on the total concentration of LAAM and its active metabolites, norLAAM and dinorLAAM, was to significantly increase AUC by 43{\%} (p < .001), Cmax by 30{\%} (p = .013), and C min by 59{\%} (p = .004) while decreasing Tmax (p = .05). Cognitive deficits over the seven-day study period as measured by the Mini-Mental State Examination, opioid withdrawal symptoms as measured by the Objective Opioid Withdrawal Scale, or complaints of adverse symptoms were not observed. Methadone and LAAM did not affect DLV concentrations. The findings from this study show that DLV treatment in methadone- or LAAM-maintained individuals results in altered opioid pharmacokinetics with an increased exposure and potential risk for opioid toxicity with methadone or LAAM treatment and an increased risk of cardiac toxicity with concomitant LAAM and DLV administration.",
author = "McCance-Katz, {Elinore F.} and Rainey, {Petrie M.} and Patrick Smith and Morse, {Gene D.} and Gerald Friedland and Beth Boyarsky and Marc Gourevitch and Peter Jatlow",
year = "2006",
doi = "10.1080/10550490500419029",
language = "English (US)",
volume = "15",
pages = "23--34",
journal = "American Journal on Addictions",
issn = "1055-0496",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Drug interactions between opioids and antiretroviral medications

T2 - Interaction between methadone, LAAM, and delavirdine

AU - McCance-Katz, Elinore F.

AU - Rainey, Petrie M.

AU - Smith, Patrick

AU - Morse, Gene D.

AU - Friedland, Gerald

AU - Boyarsky, Beth

AU - Gourevitch, Marc

AU - Jatlow, Peter

PY - 2006

Y1 - 2006

N2 - Understanding the drug interactions between antiretrovirals and opioid therapies may decrease toxicities and enhance adherence with improved HIV outcomes in opioid-dependent individuals. The authors report the results of a clinical pharmacology study designed to determine whether significant pharmacokinetic and/or pharmacodynamic interactions occur between the non-nucleoside reverse transcriptase inhibitor, delavirdine (DLV), and either methadone or leva-alpha acetyl methadol (LAAM) (n = 40). DLV significantly decreased methadone clearance (p = .018) and increased the methadone elimination half-life (p < .001) with a resultant increase in AUC of 19% and C minof 29%. The combined effect of DLV on the total concentration of LAAM and its active metabolites, norLAAM and dinorLAAM, was to significantly increase AUC by 43% (p < .001), Cmax by 30% (p = .013), and C min by 59% (p = .004) while decreasing Tmax (p = .05). Cognitive deficits over the seven-day study period as measured by the Mini-Mental State Examination, opioid withdrawal symptoms as measured by the Objective Opioid Withdrawal Scale, or complaints of adverse symptoms were not observed. Methadone and LAAM did not affect DLV concentrations. The findings from this study show that DLV treatment in methadone- or LAAM-maintained individuals results in altered opioid pharmacokinetics with an increased exposure and potential risk for opioid toxicity with methadone or LAAM treatment and an increased risk of cardiac toxicity with concomitant LAAM and DLV administration.

AB - Understanding the drug interactions between antiretrovirals and opioid therapies may decrease toxicities and enhance adherence with improved HIV outcomes in opioid-dependent individuals. The authors report the results of a clinical pharmacology study designed to determine whether significant pharmacokinetic and/or pharmacodynamic interactions occur between the non-nucleoside reverse transcriptase inhibitor, delavirdine (DLV), and either methadone or leva-alpha acetyl methadol (LAAM) (n = 40). DLV significantly decreased methadone clearance (p = .018) and increased the methadone elimination half-life (p < .001) with a resultant increase in AUC of 19% and C minof 29%. The combined effect of DLV on the total concentration of LAAM and its active metabolites, norLAAM and dinorLAAM, was to significantly increase AUC by 43% (p < .001), Cmax by 30% (p = .013), and C min by 59% (p = .004) while decreasing Tmax (p = .05). Cognitive deficits over the seven-day study period as measured by the Mini-Mental State Examination, opioid withdrawal symptoms as measured by the Objective Opioid Withdrawal Scale, or complaints of adverse symptoms were not observed. Methadone and LAAM did not affect DLV concentrations. The findings from this study show that DLV treatment in methadone- or LAAM-maintained individuals results in altered opioid pharmacokinetics with an increased exposure and potential risk for opioid toxicity with methadone or LAAM treatment and an increased risk of cardiac toxicity with concomitant LAAM and DLV administration.

UR - http://www.scopus.com/inward/record.url?scp=32144461359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32144461359&partnerID=8YFLogxK

U2 - 10.1080/10550490500419029

DO - 10.1080/10550490500419029

M3 - Article

C2 - 16449090

AN - SCOPUS:32144461359

VL - 15

SP - 23

EP - 34

JO - American Journal on Addictions

JF - American Journal on Addictions

SN - 1055-0496

IS - 1

ER -